Conference Reports for NATAP

Back

HEPDART 2015: Frontiers in Drug Development for Viral Hepatitis December 6-10 2015 Wailea, HI     HCV Highlights: HepDart/AASLD - Current HCV Treatments - New HCV Treatments in Development - (01/11/16) Optimizing Outcomes in HCV Patients: Elbasvir/Grazoprevir: kidney disease/IDUs/resistance (01/04/16)   (HepDart) Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients (12/22/15)   High Efficacy of Ledipasvir/Sofosbuvir With Ribavirin In HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials (12/22/15)   Retreatment of Patients Who Failed Sofosbuvir-Based Regimens with Ledipasvir/Sofosbuvir Regimens (12/22/15)   (HepDart) PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR) (12/22/15)   (HepDart) SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 In Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection (12/22/15)   PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR) (12/22/15)   High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)   High Efficacy of Sofosbuvir/Velpatasvir Across 7 HCV Genotypes and 46 Subtypes: Pooled Data From the ASTRAL1, 2 and 3 Trials (12/14/15)   Development of Potent Novel Oral Pan-genotypic HCV Nucleotide, NS5A, NS5B Non-nucleoside, and Helicase Inhibitors (12/14/15)   Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST 1 & 2) (12/14/15)   (HepDart) Treatment With Ombitasvir/Paritaprevir/r Plus Dasabuvir With Ribavirin Was Not Associated With Changes in Renal Function: An Analysis of 1211 Patients Enrolled in Four Phase 2 and 3 Trials (12/14/15)   (HepDart) Efficacy and Safety of Ombitasvir/Paritaprevir/r + Dasabuvir ± Ribavirin According to Baseline Renal Function: Analysis of 2005 Patients Enrolled in Six Phase 3 Trials (12/14/15)   Risk of cardiomyopathy and cardiac failure among patients with evidence of hepatitis C virus infection: an administrative claims database analysis (12/14/15)   (HepDart) Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M); A Comparative Analysis of the Phase-3 ION-3 Efficacy Data to Real World Effectiveness (RWE) (12/14/15)